MedTrace Logo

Exploratory Study of OPC-12759 Ophthalmic Suspension

NCT01493180 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2015-03-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of OPC-12759 ophthalmic suspension for patients with keratoconjunctival epithelial disorder compared with sodium hyaluronate. Also, safety of OPC-12759 is to be assessed.

Conditions

  • Keratoconjunctival Epithelial Disorder

Interventions

DRUG

OPC-12759 ophthalmic suspension

OPC-12759 ophthalmic suspension 2%

DRUG

Sodium hyaluronate ophthalmic solution

Sodium hyaluronate ophthalmic solution 0.1%

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Eiji Murakami · Division Dermatilogicals and Ophtalmolgicals, Otsuka Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-11-30
Completion
2012-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01493180 on ClinicalTrials.gov